Medium materiality5/10
Guggenheim Raises Biogen Price Target to $300
Why it may matterVerify against the original reporting
The target increase and remaining gap to the target are bullish, though the signal reflects one analyst's view.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim raised its BIIB target to $300, compared with a posted price of $253.62, implying about 18% upside to the target.
- Target raised to $300
- Posted price: $253.62; implied target upside: about 18%
Key facts
- 01
Target: $300
- 02
Posted price: $253.62
- 03
Analyst firm: Guggenheim
- 04
Analyst: Yatin Suneja
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.